Calyxo, Inc. is a medical device company headquartered in Pleasanton, California, USA. The company was founded in 2016 to address the profound need for improved kidney stone treatment. Kidney stone disease is a common, painful condition that consumes vast amounts of healthcare resources each year. Our team is led by executives and investors with a proven track record of commercializing paradigm-shifting devices to meet unmet needs within urology.

Are you ready to change the future of kidney stone treatment? We are seeking high achievers who want to be part of a dynamic team working in a fun, diverse atmosphere.

Summary:

Reporting to the Regional Sales Manager, the Territory Sales Manager for our Minnesota East territory will live in or around the St. Paul or Duluth area. This position will drive high CVAC adoption among physicians while meeting or exceeding the monthly and quarterly sales quotas for this territory. This role will effectively communicate CVAC’s value proposition to new and existing customers and will qualify, train, assess, and develop accounts to adopt our technology as an integral part of their kidney stone practice. This role will represent Calyxo with honesty, integrity, and unwavering business ethics. The ideal candidate will be disciplined and have experience conducting product demonstrations. This candidate should be comfortable with frequent travel and be able to generate new sales leads on a regular basis. The candidate should be able to keep track of their sales and effectively communicate with other team members while out in the field.

Responsibilities:

Meet or exceed quarterly sales quota for the defined area.
Maintain a monthly and quarterly territory plan that outline territory sales objectives and areas of vulnerability.
Provide monthly forecasts for defined area.
Effectively communicate the value proposition of Calyxo products to customers.
Qualify, train, assess, and develop accounts to adopt Calyxo products as an integral part of their kidney stone practice with the goal of demonstrating high account adoption.
Communicate current market conditions and recommend improvements to the commercial process.
Partner with Professional Education to deliver outstanding clinical and training support to ensure physicians quickly become clinically independent.
Build and maintain relationships with key customers and KOLs within defined region.
Partner closely with the Regional Sales Manager, Sales team, and Marketing team to identify and prioritize customers for higher-level corporate relationships.
Partner with the Customer Service team to meet and exceed customer expectations.
Partner with the Regional Sales Manager and Finance team to ensure all required sales reporting forms are completed and submitted on time.
Provide support for the resolution of product complaints and/or safety issues.
Proactively support organizational goals and objectives, policies and procedures, Good Manufacturing Practices, and FDA regulations, including strict compliance with Calyxo’s Customer Relationship and the Sunshine Act policies.
Maintain a professional and credible image with key physicians, consultants, suppliers, and teammates.
Establish and maintain credentials (via RepTrax, Vendormate, etc) to enter and work in hospitals and other medical facilities as required by facility requirements.
Manage travel and expenses per approved budget.
Perform other duties as assigned.
Contribute to our culture of being collaborative, respectful, transparent, ethical, efficient, high- achieving, and fun!

Qualifications:

Education: Bachelor’s degree or equivalent experience
5+ years of outside sales/sales management experience. Medical device experience preferred
Strong track record of over-delivering revenue versus sales plan
Proficient in navigating and accelerating hospital and ASC product approval processes
Operating room experience required
Thorough knowledge of urology and urology products and strong relationships with local urologists highly desired
Successful track record of launching new and disruptive technologies and well-versed and proficient in complex reimbursement environments
Understanding of the treatment algorithm for patients with kidney stones preferred
Compliance with relevant vaccination county, state, and federal rules

At Calyxo, you will be part of a knowledgeable, high-achieving, experienced and fun team. You will work in a diverse work environment with experienced, proven leaders and have an opportunity to shape our company culture. You will experience constant learning and dynamic challenges to help you grow and be the best version of yourself.

We also offer a competitive compensation package as follows:

Base salary of $120,000 and variable compensation of $140,000 annualized
Stock options – ownership and a stake in growing a mission-driven company
Employee benefits package that includes 401(k), healthcare insurance and paid vacation

Calyxo is deeply committed to fostering an environment where diversity and inclusion are not only valued but also prioritized. We believe a diverse and inclusive community empowers us to act courageously, care deeply, and dream boldly to impact people in big ways. Diverse viewpoints bring diverse capabilities, which strengthen our focus and fuel our growth.Calyxo is proud to be an equal opportunity employer, seeking to create a welcoming and diverse environment. All applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, veteran status or any other applicable legally protected characteristics

Legal authorization to work in the United States is required. In compliance with federal law, all persons hired will be required to verify their identity and eligibility to work in the United States and to complete the required employment eligibility verification form upon hire.

Disclaimer:

At Calyxo, we prioritize a transparent and structured interview process to ensure the best fit for both our candidates and our team. Please be aware of the following:

Structured Interview Process: Our hiring process includes multiple stages of interviews where you will have the opportunity to communicate directly with Calyxo employees. This ensures that you gain a comprehensive understanding of the role and our company culture.
Verification of Identity: We do not extend job offers without first meeting candidates, either virtually or in person. This step is crucial to maintain the integrity of our hiring process and to ensure mutual alignment.
Beware of Scams: Calyxo will never request sensitive personal information, such as your full name, address, phone number, or identification documents, via email or online forms before an official interview. Calyxo representatives will always contact you using an email format of [email protected]. If you receive a request for information from any other domain, please contact us directly at [email protected] verify the legitimacy of the communication.

We appreciate your interest in joining Calyxo and look forward to getting to know you through our official channels.

About the company

Calyxo, Inc. develops medical devices for kidney stone treatment. Its products are designed for use by urologists in hospitals and clinics to treat kidney stones more effectively, prioritizing patient safety and efficient procedures. The company works closely with leading U.S. urologists to translate clinical needs into devices, focusing on making treatments safer and easier for clinicians. Unlike some competitors, Calyxo emphasizes clinician collaboration and proven clinical relevance in its device development, backed by leadership with startup and product-launch experience. The goal is to improve patient care by delivering advanced devices that help urologists achieve better clinical outcomes and expand the devices’ reach through commercialization to healthcare providers.

Company Size

201-500

Company Stage

Series F

Total Funding

$137.2M

Headquarters

Pleasanton, California

Founded

2016

Get referred to Calyxo

See people who can refer or advise you

Simplify's Take

What believers are saying

Calyxo closed a $40 million Series F in April 2026, extending runway.
The company reported 40,000 patients treated, signaling real-world traction beyond early adopters.
AUA2026 data emphasized better stone clearance, safety, and efficiency, strengthening sales conversations.

What critics are saying

Boston Scientific launched Asurys in March 2026, directly attacking Calyxo's irrigation advantage.
Calyxo still depends on one product platform, making CVAC setbacks existential within 24 months.
Commercial expansion needs more evidence; reimbursement friction can slow hospital adoption despite 40,000 treatments.

What makes Calyxo unique

CVAC System uses continuous aspiration, unlike basket-based ureteroscopy, for fuller stone clearance.
FDA cleared CVAC in 2024; Calyxo added image processor software version 1.5 in May 2026.
AUA2026 featured ten Calyxo abstracts, reinforcing clinical evidence and procedural differentiation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Stock Options

Growth & Insights and Company News

Headcount

6 month growth

1 year growth

2 year growth

Innovation Tri-Valley Leadership Group

May 13th, 2026

Valley Reveals 2026 #GameChangers Honorees Ahead of Ninth Annual Awards Celebration

Valley reveals 2026 #gamechangers honorees ahead of ninth annual awards celebration. Pac-12, Inertia Fusion Energy, SavvyMoney, Calyxo, and Stanford Health Care Tri-Valley Named Among Region's Most Transformative Companies and Institutions DUBLIN, Calif. - 6 May 2026 - Innovation Tri-Valley Leadership Group (ITV) today announced the honorees for the ninth annual #GameChangers Awards - the Tri-Valley's signature celebration of breakthrough innovation, visionary leadership, and the companies and individuals reshaping one of the most dynamic regional economies in the world. The 2026 honorees represent the full breadth of the Tri-Valley's innovation ecosystem: a reinvented sports and entertainment powerhouse, a fusion energy company that may hold the key to the planet's clean energy future, a fintech platform changing how millions of Americans understand and manage credit, a medical device company attacking one of urology's most painful and persistent problems, and a healthcare institution that has fundamentally transformed how Tri-Valley residents access world-class care. The awards will be presented on Thursday, May 21, 2026, from 5:30 to 8:00 PM at The Roundhouse at Bishop Ranch in San Ramon. This year's honorees include: PAC-12 CONFERENCE - San Ramon Innovation in Sports & Entertainment Few institutions in American sports have undergone a transformation as dramatic - or as closely watched - as the Pac-12 Conference. Having relocated its operations to San Ramon, the Pac-12 is rewriting its own story from the heart of the Tri-Valley, building a next-generation model for collegiate sports and entertainment that leverages Silicon Valley's proximity, the Bay Area's media infrastructure, and a legacy brand that generations of fans across the western United States know and love. The Pac-12's reinvention is not just a sports story. It is a story about what it looks like when a storied institution bets on the Tri-Valley as the place to write its next chapter. INERTIA FUSION ENERGY - Livermore Innovation in Energy & Deep Technology Livermore has long been home to some of the most ambitious science in the world - and Inertia Fusion Energy is squarely in that tradition. Building on the landmark fusion ignition achieved at Lawrence Livermore National Laboratory in December 2022, Inertia Fusion Energy is working to translate that historic scientific breakthrough into a viable, commercially deployable clean energy technology. If successful, the implications are civilization-scale: abundant, carbon-free energy produced from the same physics that powers the stars. That this work is developing in Livermore is not a coincidence. It is the result of decades of scientific investment that the entire region has taken stake in. SAVVYMONEY - Dublin Innovation in Financial Technology The vast majority does not fully understand their credit score - a number that shapes their ability to buy a home, secure a loan, and build financial stability. SavvyMoney, headquartered in Dublin, is changing that. The company's credit score and financial wellness platform is embedded in the digital banking experiences of credit unions and financial institutions serving tens of millions of consumers nationwide, providing real-time credit insights, personalized offers, and the kind of financial clarity that was previously available only to those who knew where to look and what to look for. SavvyMoney's work is not just fintech. It's financial equity, shared at scale, and built in the Tri-Valley. CALYXO - Pleasanton Innovation in Biotechnology & Medical Devices Kidney stones affect one in ten Americans and represent one of the most painful and costly conditions in urology - with recurrence rates that make treatment a recurring challenge for millions of patients. Calyxo, based in Pleasanton, has developed a breakthrough medical device technology designed to dramatically improve the efficiency and outcomes of kidney stone treatment, reducing procedure time, improving stone clearance, and enabling patients to return to health faster. The company's technology is the product of deep clinical insight and rigorous engineering - and its trajectory from Pleasanton to surgical suites across the country is precisely the kind of innovation story the Tri-Valley was built to produce and tell. STANFORD HEALTH CARE TRI-VALLEY - Founders Award Transformative Impact on the Tri-Valley Innovation Ecosystem The annual Founders Award honors an individual or organization whose contribution to the Tri-Valley's innovation ecosystem transcends a single sector or a single year - whose presence has fundamentally changed what is possible for the region and the people who live here. This year, that recognition is given to Stanford Health Care Tri-Valley. When Stanford Health Care opened its Tri-Valley campus, it did not simply add another hospital to a growing region. It signaled to the world that the Tri-Valley was a place worthy of competitive institutional investment - and it delivered on that signal by bringing the clinical expertise, research capabilities, and care standards of one of the world's leading academic medical centers to the doorstep of Tri-Valley families. The impact has been profound: on patient outcomes, on the region's ability to attract and retain top talent, on the broader healthcare ecosystem, and on the confidence of every company and family that has chosen to build a home in the region. Stanford Health Care Tri-Valley has not just served this community. It has strengthened it and made life and living sought after in the Tri-Valley. The #GameChangers Awards - Nine Years of Honoring the Tri-Valley's Best Now in its ninth year, the #GameChangers Awards has become the most anticipated event on the Tri-Valley's innovation calendar - a high-energy reception and awards ceremony that unites the region's founders, funders, civic leaders, and entrepreneurs to honor the companies and individuals transforming the Tri-Valley into a global innovation hub. "The 2026 cohort is extraordinary - and equally emblematic of a Tri-Valley that is not waiting for the future to arrive," said Katie Marcel, CEO, Innovation Tri-Valley. "This region's innovation story is a huge contribution to the leadership of California. It is a bearer of hope for the world." The ninth annual #GameChangers Awards will feature a hosted reception and the presentation of this year's honorees in a program designed to energize and inspire everyone in the room. Tickets, sponsorship opportunities and more information are available at [email protected]. ###. ABOUT INNOVATION TRI-VALLEY LEADERSHIP GROUP Innovation Tri-Valley Leadership Group (ITV) is a collaborative network of corporate leaders, elected and civic officials, educators, and regional champions dedicated to advancing the Tri-Valley as a globally recognized hub of technology, entrepreneurship, and economic vitality. Spanning the cities of Dublin, Livermore, Pleasanton, San Ramon, and the Town of Danville, the Tri-Valley is home to two national research laboratories - Lawrence Livermore National Laboratory and Sandia National Laboratories - more than 700 technology companies, and a regional innovation economy generating $52 billion in GDP. ITV connects the dots between the public and private sectors, amplifies the region's breakthrough companies and people, and shapes the long-term economic future of one of the Bay Area's fastest-growing and most dynamic regions. Learn more at innovationtrivalley.org. MEDIA CONTACT

Business Wire

Apr 16th, 2026

Calyxo Secures $40 Million Series F Financing as CVAC System Surpasses 40,000 Patients Treated for Kidney Stone Removal

Calyxo, Inc., a medical device company redefining kidney stone treatment, today announced the closing of a $40 million Series F financing round, led by Ally ...

Medical Device Network

Apr 15th, 2026

Calyxo raises $40m to advance kidney stone removal system.

Calyxo raises $40m to advance kidney stone removal system. Calyxo intends to use the funds towards generating further clinical and economic evidence for its CVAC system for kidney stone clearance. Calyxo has raised $40m in a financing round; at the same time, the company has achieved a milestone of 40,000 kidney stone removal procedures completed with its central venous access catheter (CVAC) system. The Series F financing round was led by Ally Bridge Group and Janus Henderson Investors, with continued support from Questa Capital, Avidity Partners, and CRG. Calyxo's CVAC system provides continuous aspiration of stone fragments during and after laser lithotripsy to support more complete kidney stone clearance. The system obtained US Food and Drug Administration (FDA) clearance in March 2024. Calyxo plans to apply the latest funds towards clinical and health economic evidence generation through ongoing and future studies to evaluate the system's long-term outcomes and downstream healthcare utilisation, along with making expansions to its commercial infrastructure. Past research of Calyxo's CVAC has found that 95% of patients experienced no adverse events (AEs) following its use alongside steerable ureteroscopic renal evacuation (SURE) for kidney stone clearance, versus 83.5% who received standard ureteroscopy. Coinciding with the latest financing round, Calyxo shared that it has recently completed 40,000 kidney stone removal procedures using its CVAC system. Calyxo CEO, Joe Catanese, commented: "Real-world experience, together with an established body of clinical evidence, indicates that the CVAC system is moving beyond early adoption and becoming an important part of the standard of care in kidney stone treatment. This financing allows us to move faster in advancing our technology and expanding the evidence base to further improve patient care." According to the American Urological Association (AUA), approximately 10% of people in the US will have a kidney stone at some point in their lives. In the broader kidney care space, funding is an ongoing challenge. An American Society of Nephrology (ASN) report from November 2025 highlights that the US funding imbalance in kidney care has stalled progress, leaving dialysis as the default therapy for kidney failure, despite its "debilitating impact" and poor survival outcomes. To turn the tide on poor survival outcomes for conditions such as end-stage kidney disease (ESKD), advocates are growing more vocal about shifting the focus to kidney care, and have urged the World Health Organization (WHO) to classify kidney disease as a non-communicable disease priority globally. Give your business an edge with its leading industry insights.

StreetInsider

Apr 14th, 2026

Calyxo raises $40M Series F as CVAC kidney stone system treats 40,000 patients

Calyxo, a medical device company focused on kidney stone treatment, has closed a $40 million Series F financing round led by Ally Bridge Group and Janus Henderson Investors. Questa Capital, Avidity Partners and CRG also participated. The funding follows a milestone of 40,000 patients treated with Calyxo's CVAC System, an aspiration-based stone removal device. The system uses irrigation and vacuum aspiration to continuously clear stone fragments during procedures, enabling more complete stone clearance. Proceeds will support commercial expansion, clinical evidence generation through ongoing studies evaluating long-term outcomes, and continued innovation in kidney stone care. The CVAC System received FDA clearance in 2024 and is positioned as an all-in-one solution for minimally invasive kidney stone removal.

Business Wire

May 14th, 2024

Study Presented At Aua Shows Superior Kidney Stone Clearance Rates For Sure Procedure Using Calyxo’S Cvac System Vs Standard Urs

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, has announced that positive study results for its CVAC System were presented last week at the American Urological Association (AUA) Annual Meeting in San Antonio. The CVAC System, a revolutionary technology that is designed for complete kidney stone removal, was the focus of the prospective, randomized, multi-center ASPIRE study, which compared the safety and efficacy of steerable ureteroscopic renal evacuation (SURE) vs ureteroscopy (URS) with basketing. The 30-day results of the ASPIRE study were presented at the AUA Meeting by urologist Thomas Chi, MD of the University of California, San Francisco. In 101 patients, SURE demonstrated statistically superior stone clearance and significantly lower residual stone volume compared to standard URS. Unlike standard URS, the CVAC System achieved these results independent of baseline stone burden. Safety was comparable between groups

Calyxo

Territory Sales Manager

About the job

About the company

Get referred to Calyxo

Simplify's Take

What believers are saying

What critics are saying

What makes Calyxo unique

Benefits

Growth & Insights and Company News

6 month growth

1 year growth

2 year growth